Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2003

Filing Date
Filed March 15, 2004
Period End
December 31, 2003
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed March 15, 2004. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $30.3 milliona, or $0.93 per share, for 2003, compared with a net loss of $94.5 million, or $3.10 per share, in 2002.

Total revenues rose to $139.1 millionb from $18.0 million, driven mainly by $90.9 million of sponsored development reimbursements and $38.0 million of amortized upfront fees under the Pfizer collaboration for indiplon, its lead insomnia candidate. Research and development expenses increased to $177.3 million, and the company stated it expects R&D expenses to decrease in 2004 as the indiplon Phase III program completes. The company expects to file a New Drug Application for indiplon in mid-2004 and anticipates its first product revenues in 2005, with a return to profitability expected that year.

Year-end 2003 cash, cash equivalents and short-term investments totaled $453.2 millionc, up from $244.7 million a year earlier, reflecting the $100.0 million Pfizer upfront payment and $187.4 million of net proceeds from a September 2003 stock offering. The company also recorded a one-time gain of approximately $18.0 million on the sale of its former headquarters to Pfizer. Accumulated deficit stood at $232.2 million, and the company stated its existing capital resources are sufficient for at least the next 12 months.

Subsequent to year-end, on February 26, 2004, the company agreed to acquire Wyeth's financial interest in indiplon for approximately $95 milliond ($50 million in cash and $45 million in common stock), reducing its royalty obligation to DOV on indiplon sales from six percent to three and one-half percent. The transaction was scheduled to close on March 15, 2004. The company also disclosed a pending arbitration filed by The Salk Institute over alleged unpaid milestone payments, which management believes will not have a material adverse effect.

Key Highlights

  1. Net loss narrowed to $30.3 million ($0.93 per share) in 2003 from $94.5 million ($3.10 per share) in 2002.
  2. Total revenues increased to $139.1 million from $18.0 million, primarily from Pfizer collaboration reimbursements and amortized upfront fees.
  3. Research and development expenses rose to $177.3 million in 2003 from $108.9 million in 2002; the company expects R&D expenses to decrease in 2004 as the indiplon Phase III program ends.
  4. Cash, cash equivalents and short-term investments reached $453.2 million at December 31, 2003, versus $244.7 million a year earlier.
  5. Indiplon NDA filing is planned for mid-2004; the company expects FDA approval in 2005 and first product revenues in 2005.
  6. Pfizer provided a $100 million upfront payment and up to $300 million in pre-commercialization milestones for indiplon, with a committed secured credit facility of up to $175 million.
  7. Agreed on February 26, 2004 to acquire Wyeth's indiplon financial interest for about $95 million, lowering the DOV royalty obligation from six percent to three and one-half percent.

Frequently Asked Questions

  1. What is the company's lead product candidate and what is its regulatory status?

    The lead candidate is indiplon, a non-benzodiazepine GABA-A receptor agonist being developed for insomnia. The company stated it is in Phase III trials in collaboration with Pfizer and plans to file a New Drug Application for both formulations in mid-2004.

  2. How is the Pfizer collaboration structured?

    Pfizer made a $100 million upfront payment and may pay up to $300 million in additional pre-commercialization milestones. Pfizer bears most third-party development, marketing and commercialization costs, except $30 million of specified development costs borne by Neurocrine. Neurocrine would receive a percentage of worldwide indiplon sales and co-promotion payments, and would fund a 200-person sales force with Pfizer support after NDA filing.

  3. Why did the net loss decrease significantly in 2003?

    The filing attributes the decrease primarily to increased revenue under the Pfizer collaboration agreement, partially offset by higher external development costs and the $17.9 million gain on the sale of the corporate headquarters.

  4. What are the main risks highlighted for investors?

    The filing highlights risks that clinical trials may fail to demonstrate safety and efficacy, dependence on Pfizer for indiplon funding and commercialization (Pfizer may terminate on 180 days' notice), uncertainty of regulatory approval, lack of marketing experience, reliance on contract manufacturers, a history of losses with expected losses in 2004, and possible need for additional funding.

  5. Is there any pending litigation?

    The Salk Institute filed a demand for arbitration on June 27, 2003, seeking additional milestone payments under a 1993 license agreement related to CRF antagonists. Management believes the company has complied with the agreement and expects the matter will not have a material adverse effect, though outcomes cannot be assured.